### PATENT COOPERATION TREATY

TRANSLATION From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) See form PCT/ISA/210 Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION WOB03INRORUS See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) 14.01.2005 PCT/FR2005/000093 15.01.2004 International Patent Classification (IPC) or both national classification and IPC C12N15/53, C12N15/80, C12N9/02, C12N1/15, C12P21/02 Applicant INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Reasoned statement under Rule 43his.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized officer Name and mailing address of the ISA/EP Facsimile No. Telephone No.

Box	No. I	I Basis of this opinion						
1.		th regard to the language, this opinion has been established on the basis of the international application in the language in which it w.d, unless otherwise indicated under this item.	as					
		This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (und	er					
		Rule 12.3 and 23.1(b)).						
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:							
	a. type of material							
		a sequence listing						
		table(s) related to the sequence listing						
	b.	format of material						
		in written format						
		in computer readable form						
	c.	time of filing/furnishing						
		contained in the international application as filed.						
		filed together with the international application in computer readable form.						
		furnished subsequently to this Authority for the purposes of search.						
2								
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application filed or does not go beyond the application as filed, as appropriate, were furnished.						
4.	Add	ditional comments:						
		•						
		·						

Box No. II Priority									
The following document has not yet been furnished:									
copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).									
translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).  Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on									
the assumption that the relevant date in the claimed priority date.									
This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.									
3. Additional observations, if necessary:									
see supplemental sheet									

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1. Statement						
Novelty	(N)	Claims 6, 7, 10-13 Claims 1-5, 8, 9, 14-20	YES NO			
Inventivo	e step (IS)	Claims 1-20	YES NO			
Industria	al applicability (IA)	Claims 1-20 Claims	YES NO			
2. Citations an	d explanations:					
1.	D1: ALVE effi basi APPL 70, 6379 D2: MART oxid inte	is made to the following documents:  S, ALEXANDRA M. C. R. ET AL, "Highly cient production of laccase by the diomycete <i>Pycnoporus cinnabarinus</i> ,"  IED AND ENVIRONMENTAL MICROBIOLOGY, Vol.  No. 11, November 2004 (2004-11), pages 1-6384, XP002341841, ISSN: 0099-2240  INEZ, A.T., "Fungal metalloenzymes 1:2ing aromatic compounds of industrial 1:2:1:2:1:2:1:2:1:2:1:2:1:2:1:2:1:2:1:2				
	pela D3: LOMA lacc Pycn indu Vol. XP00 D4: SIGO prod	<pre><http: html="" lignina="" pelas="" s="" www.cib.csic.ex=""> [acquired 2004-09-10] SCOLO, A. ET AL, "Overproduction of ase by a monokaryotic strain of oporus cinnabarinus using ethanol as cer," JOURNAL OF APPLIED MICROBIOLOGY,    94, No. 4, 2003, pages 618-624, 2295716, ISSN: 1364-5072 ILLOT JEAN-CLAUDE ET AL, "Laccase uction by a monokaryotic strain of oporus cinnabarinus derived from a</http:></pre>				

International application No.
PCT/FR2005/000093

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement dikaryotic strain," WORLD JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, Vol. 15, No. 4, August 1999 (1999-08), pages 481-484, XP008035159, ISSN: 0959-3993 D5: OTTERBEIN LUDOVIC ET AL, "Molecular cloning of the cDNA encoding laccase from Pycnoporus cinnabarinus I-937 and expression in Pichia pastoris," EUROPEAN JOURNAL OF BIOCHEMISTRY, Vol. 267, No. 6, March 2000 (2000-03), pages 1619-1625, XP002295717, ISSN: 0014-2956 D6: RECORD ERIC ET AL, "Expression of the Pycnoporus cinnabarinus laccase gene in Aspergillus niger and characterization of the recombinant enzyme," EUROPEAN JOURNAL OF BIOCHEMISTRY, Vol. 269, No. 2, January 2002 (2002-01), pages 602-609, XP002295718, ISSN: 0014-2956

- 2. NOVELTY (PCT Article 33(2))
- 2.1 The present application fails to comply with the requirements of PCT Article 33(1) since the subject matter of claims 1-5, 8, 9 and 14-20 does not fulfil the criterion of novelty defined in PCT Article 33(2).
- 2.2 Document D3 describes (see entire document) a method for preparing endogenous laccase from Pycnoporus cinnabarinus, the said method being performed by overexpression of the encoding gene for this protein in a monokaryotic strain of filamentous fungi of P. cinnabarinus and

Box No. V

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

comprises:

- a step for cultivating this monokaryotic strain containing the encoding gene for endogenous laccase, the expression of which is under the control of the endogenous promoter,
- a step for inducing the above-mentioned promoter by adding ethanol,
- the recovery of the laccase.

The expressions "(a given) recombinant (protein)" and "transformed (using an expression vector)" do not make it possible to clearly and unambiguously distinguish the laccase and the strain from the claims of a corresponding laccase and "wild-type" strain.

Expressions such as "if necessary" ["le cas échéant"] and "particularly" ["notamment"] do not have any limiting effect on the scope of a claim, which amounts to saying that the feature that follows such an expression should be considered entirely optional.

Consequently, the subject matter of claims 1-5, 8 and 18-20 is anticipated by document D3.

Moreover, document D3 explicitly refers to document D5 (see entire document and AF170093 having 100% identity in an overlap of 3331 base pairs with SEQ ID NO: 1 and Q9UVQ2 having 100% identity in an overlap of 518 amino acids with SEQ ID NO: 2), which provides more detailed information on

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

certain features; the teaching of this document D5 must therefore be considered to be incorporated in document D3. Consequently, the subject matter of claim 9 is also anticipated by document D3.

- 2.3 Document D4 describes (see entire document) a method that is similar, but that comprises a step for induction by adding ferulic acid. Thus, the same objections are applicable mutatis mutandis.
- 2.4 Document D5 (see entire document) describes the expression of laccase from *P. cinnabarinus* in a strain of *Pichia pastoris* transformed by means of an expression vector containing the nucleotide sequence represented by SEQ ID NO: 1 that encodes the laccase represented by SEQ ID NO: 2, wherein the expression is placed under the control of the exogenous promoter pAox1.

Since the promoter pAox1 may be considered to be "a promoter corresponding to the sequence SEQ ID NO: 3 or any sequence derived from this promoter by substitution, addition or deletion of one or more nucleotides and retaining the property of being a promoter of the expression of sequences," document D5 describes, in combination, all of the features defined in claims 14-18 and 20. The subject matter of these claims is therefore not novel.

2.5 Document D6 describes (see entire document) the expression of laccase from P. cinnabarinus as does D5, but in a strain of Aspergillus niger and using

International application No.
PCT/FR2005/000093

Box No. V
Reasoned statement under Rule 43bis.1(a)(i) with regard to novelly, inventive step or industrial applicability; citations and explanations supporting such statement

the exogenous promoter pgpdA. Thus, the same

the exogenous promoter pgpdA. Thus, the same objections are applicable, mutatis mutandis.

- 3. INVENTIVE STEP (PCT Article 33(3))
- 3.1 The present application fails to comply with the conditions set out in PCT Article 33(1) since the subject matter of claims 1-20 does not involve an inventive step as defined in PCT Article 33(3)).
- 3.2 Document D3, which is considered to be the closest prior art, describes (see entire document) a method for preparing endogenous laccase from *Pycnoporus cinnabarinus*, the said method being performed by overexpression of the encoding gene for this protein in a monokaryotic strain of filamentous fungi of *P. cinnabarinus* and comprises:
  - a step for cultivating this monokaryotic strain containing the encoding gene for endogenous laccase, the expression of which is under the control of the endogenous promoter,
  - a step for inducing the above-mentioned promoter by adding ethanol,
  - the recovery of the laccase.
  - The subject matter of the present application is different in that a host cell of *P. cinnabarinus*, transformed by means of an expression vector, is used for the recombinant preparation of given proteins.
- 3.3 The problem that the present application proposes

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

to solve may be considered to be to provide a method for the recombinant preparation of given proteins. The solution to the problem is the use of a host cell of *P. cinnabarinus* transformed by means of an expression vector.

3.4 The solution proposed in the present application (see claims 1-20) is not considered inventive for the following reasons. Document D2 (see paragraph 5) discloses the *P. cinnabarinus* strain as a host cell as well as the expression of endogenous laccase and the expression of an exogenous peroxidase of *Pleurotus eryngii* in this cell.

Consequently, in light of the prior art of D3 and D2, it is obvious for a person skilled in the art to use a host cell of transformed *P. cinnabarinus* for the recombinant preparation of given proteins.

The claims do not contain any features which, when combined with the features of any claim to which they refer, satisfy the requirements of the PCT with regard to inventive step.

3.5 Moreover, D1 (see boxes II and VI below) is part of the prior art relating to claims 4, 5, 12, 13 and 17, and the claims that refer to these claims, i.e. claims 6, 7 and 18-20. The subject matter of these claims does not involve an inventive step as defined in PCT Article 33(3) since D1 demonstrates (see abstract) that the host cell of P. cinnabarinus can successfully be used for the production of other proteins.

Box	No. VI	Certain documents cited			
1.	Certain	published documents (Rule 43bis.1 and 70.10)			
		Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
	_			()	(LL) Monte year)
			•		
2.	Non-wri	tten disclosures (Rule 43bis.1 and 70.9)		<del></del>	
		Kind of non-written disclosure	Date of non-written disc (day/month/year)	losure referring	e of written disclosure g to non-written disclosure (day/month/year)
		,			
		•			•
se	e fo	rm 210			

International application No.
PCT/FR2005/000093

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

ntinuation ot:

### Boxes II and VI

The priority claimed appears to be inadmissible because the sequences with SEQ ID NOs: 14-18, figures 12 and 13 and claims 4, 5, 12, 13 and 17 are not present in the priority application. Consequently, document D1 is part of the prior art and may be used to evaluate novelty and inventive step in accordance with PCT Article 33(2) and (3).